Nov. 7 (Bloomberg) -- Transgene SA and Jennerex Biotherapeutics said the high doses of their JX594/TG6006 therapy improved overall survival in advanced liver cancer patients, citing a mid-stage study of 30 patients.
Patients receiving the treatment at the higher dose lived a medial of 13.8 months, compared with 6.7 months for those who received the lower dose, Strasbourg, France-based Transgene and San Francisco-based Jennerex said in an e-mailed statement today. The findings are being presented at the American Association for the Study of Liver Diseases meeting in San Francisco today.
JX594/TG6006 is a virus that is engineered to target and destroy cancerous cells, according to the companies.
To contact the reporter on this story: Kristen Hallam in London at email@example.com
To contact the editor responsible for this story: Phil Serafino at firstname.lastname@example.org